MARKET WIREStockInvest.us • 22h ago
Skye Bioscience Stock Price Forecast. Should You Buy SKYE?StockInvest.us report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
Why SKYE Stock dropped -2.29% Today — RQD Quant Desk Flash
$1.28 -2.29% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.27
Skye Bioscience Inc. (SKYE) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $5.7M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on SKYE Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is SKYE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Skye Bioscience Inc. (NASDAQ: SKYE) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.28 (-2.29% 1D, market cap $5.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SKYE ranks #656 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does SKYE compare to ACXP and ALZN in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SKYE carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACXP (Acurx Pharmaceuticals Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M) and ALZN (Alzamend Neuro Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M). Among the 5-stock peer group, SKYE leads on earnings multiple (N/A) while SKYE leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for SKYE?
▼
Per SKYE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001516551), Skye Bioscience Inc. generated $162.9M in revenue (+92.6% YoY), -$55.9M in net income, and -$43.1M in free cash flow against $28.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.27 (-0.60%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-10.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SKYE)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY SKYE SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$1.53+5.9% Next Q
42
Q2 (-2Q)Grade E$1.62-10.5% Next Q
39
Q3 (-1Q)Grade E$1.45-11.7% Next Q
37
CurrentGrade E$1.28-8.7% Hist 90D α
34
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a SKYE Turnaround Squeeze
While SKYE currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.69) and Max Pain ($1.34) forces dealer call-delta covering toward $13.44.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $SKYE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SKYE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why SKYE Stock dropped -2.29% Today — RQD Quant Desk Flash
Skye Bioscience Inc. (SKYE) dropped -2.29% to $1.28, trading at 2% of its 52-week range ($1.25 – $12.8). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($1.25 – $12.8) with RSI-14 at 32 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.28 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live SKYE Headlines & Catalysts
MARKET WIREMoomoo • 1d ago
SKYE BIOSCIENCE INC (SKYE) Stock Forum and DiscussionMoomoo report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Two holders report shared voting power over the same 263,560 Skye Bioscience (SKYE) shares.Stock Titan report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
SKYE Q3'26 Earnings: revenue estimate is 0 USDTradingView report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 1d ago
Kazia Therapeutics Limited (KZIA) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 1d ago
Most Active Stocks Today: U.S. MarketTradingKey report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
CATALYSTTradingKey • 1d ago
Top U.S. Stock Gainers: Biggest Price IncreasesTradingKey report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 1d ago
Complete U.S. Stocks List: Prices, Performance and Key DataTradingKey report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SKYE)
- ✓Walkthrough of SKYE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
SKYE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -81.61%🛡️ HOLDING TREND SUPPORT
2026-11-03O $1.31H $1.31L $1.28C $1.28VOL 40.6K
RES: $6.64SUP: $1.22SMA50: $1.69SMA200: $4.79
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
SKYE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +92.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on SKYE today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for SKYE. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SKYE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SKYE)
Health Care Rank #656 of 1015
⚔️ ACXP vs SKYE Full Matrix →
1. Head-to-Head Health Care Peer Comparison (SKYE vs. ACXP, ALZN, BGMS, LGVN)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Skye Bioscience Inc. (SKYE) ranks #656 by composite RQD confidence (34/100, grade E) and #930 by equity capitalization ($5.7M). Within this direct 5-issuer industry benchmark cohort, SKYE leads on earnings valuation at N/A trailing P/E, while SKYE leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BGMS currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with SKYE at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SKYE
ACTIVE
Skye Bioscience Inc. | E | 34/100 | — | — | -35.0% | -2.29% | $5.7M | Benchmark Subject |
| ACXP Acurx Pharmaceuticals Inc. | E | 33/100 | — | — | -35.0% | -2.80% | $5.8M | /acxp-vs-skye → |
| ALZN Alzamend Neuro Inc. | E | 34/100 | — | — | -35.0% | -0.82% | $5.8M | /alzn-vs-skye → |
| BGMS Bio Green Med Solution Inc. | D- | 38/100 | — | — | -35.0% | +8.43% | $6.0M | /bgms-vs-skye → |
| LGVN Longeveron Inc. (Class A) | E | 27/100 | — | 67.0% | -35.0% | -4.57% | $5.3M | /lgvn-vs-skye → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001516551 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Skye Bioscience Inc. (SKYE) reported GAAP revenue of $162.9M (+92.6% vs. FY2024 revenue of $84.5M , and +67.4% cumulative change since FY2023) , GAAP net income of -$55.9M, operating cash flow of -$43.1M, and free cash flow of -$43.1M (-60.5% YoY). On the balance sheet, SKYE closed FY2025 with $28.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $162.9M | -$55.9M | -$43.1M | -$43.1M | $28.3M | — |
| FY2024 (FY) | 2024-12-31 | $84.5M | -$26.6M | -$25.2M | -$26.8M | $72.8M | — |
| FY2023 (FY) | 2023-12-31 | $97.3M | -$37.6M | -$14.0M | -$14.0M | — | — |
3. SKYE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs SKYE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Skye Bioscience Inc. (NASDAQ: SKYE) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.28 (-2.29% 1D, market cap $5.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SKYE ranks #656 in composite RQD confidence.
How does SKYE compare to ACXP and ALZN in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SKYE carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACXP (Acurx Pharmaceuticals Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M) and ALZN (Alzamend Neuro Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M). Among the 5-stock peer group, SKYE leads on earnings multiple (N/A) while SKYE leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for SKYE?
Per SKYE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001516551), Skye Bioscience Inc. generated $162.9M in revenue (+92.6% YoY), -$55.9M in net income, and -$43.1M in free cash flow against $28.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is SKYE trading relative to its 50-day, 200-day, and 52-week technical levels?
SKYE last traded at $1.28 (-2.29% on volume of 40,559 shares), positioning the stock -24.26% below its 50-day simple moving average ($1.69) and -73.28% below its 200-day simple moving average ($4.79). Across its 52-week range of $1.25 to $12.80, SKYE sits at the 0.3% percentile with a 14-day RSI of 32.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.12 to $1.44).
ROARABLE RATING BRIEF • RQD 34/100 (E)
✓ SEC XBRL & RQD VERIFIED
SKYE — Skye Bioscience Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Skye Bioscience Inc. (SKYE) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.28 (-2.29% 1D, market capitalization $5.7M).
- Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Skye Bioscience Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry,. The FY 2025 and FY 2024 financials report revenue of — in each year, so the source data shows no reported revenue in the periods covered.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Skye Bioscience Inc. (SKYE) reported $162.9M in annual revenue (up from $84.5M in FY2024, +92.6% YoY) and -$55.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($97.3M revenue, -$37.6M net income) through FY2025, SKYE scaled operating cash flow to -$43.1M and free cash flow to -$43.1M, backed by $28.3M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.25 – $12.80 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
The source data therefore identifies no upstream suppliers, downstream customers, or sector-correlated counterparties for SKYE. Sector and industry classification (Health Care; Biotechnology: Pharmaceutical Preparations) are the only sector-level context available.
- Key Question #1: Can SKYE sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $162.9M and free cash flow of -$43.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is SKYE's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
SKYE Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Skye Bioscience Inc. (SKYE) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE StockInvest.us • 22h ago
Skye Bioscience Stock Price Forecast. Should You Buy SKYE? StockInvest.us report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Moomoo • 1d ago
SKYE BIOSCIENCE INC (SKYE) Stock Forum and Discussion Moomoo report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Two holders report shared voting power over the same 263,560 Skye Bioscience (SKYE) shares. Stock Titan report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
SKYE Q3'26 Earnings: revenue estimate is 0 USD TradingView report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Kazia Therapeutics Limited (KZIA) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 1d ago
Most Active Stocks Today: U.S. Market TradingKey report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST TradingKey • 1d ago
Top U.S. Stock Gainers: Biggest Price Increases TradingKey report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 1d ago
Complete U.S. Stocks List: Prices, Performance and Key Data TradingKey report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
SKYE Bull vs. Bear Conversation Board — What's Your Call at $1.28?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SKYE 🐻 33% BEARISH CONVICTION
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH
🎯 Target: $1.61 (+25.8%)
📌 Pinned Debate The RQD rating's forensic balance sheet pillar still scores 10 / 20, with an Altman Z-Score of 2.5 and a Debt/Equity ratio of 0.5 that
Long SKYE at $1.28 targeting $1.61. The RQD rating's forensic balance sheet pillar still scores 10 / 20, with an Altman Z-Score of 2.5 and a Debt/Equity ratio of 0.5 that show the company is not yet in distress territory on those measures.. Institutional whale score is 3/20 and the risk/reward vs. the $1.25 52-week low is skewed heavily in favor of bulls.
VolSurface_Trader 🐂 BULL
Both sides have a point here — SKYE's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH
🎯 Target: $1.05 (-18.0%)
Spot @ $1.28 Cash fell from $68.4M to $5.9M across the reported fiscal years while the company generated no revenue, and FCF was -$43.1M in FY 2025
Fading this rally in SKYE at $1.28. Cash fell from $68.4M to $5.9M across the reported fiscal years while the company generated no revenue, and FCF was -$43.1M in FY 2025 with ROIC at -35%.. With a beta of 1.0 and the stock sitting at $1.28 (52-wk range $1.25–$12.80), the easy multiple expansion is already priced in.